Influenza A HA Recombinant Rabbit Monoclonal Antibody (133), Invitrogen™

Description

• This product is preservative free
• It is recommended to add sodium azide to avoid contamination (final concentration 0.05%-0.1%)
• Recombinant rabbit monoclonal antibodies are produced using in vitro expression systems
• The expression systems are developed by cloning in the specific antibody DNA sequences from immunoreactive rabbits
• Then, individual clones are screened to select the best candidates for production
• The advantages of using recombinant rabbit monoclonal antibodies include: better specificity and sensitivity, lot-to-lot consistency, animal origin-free formulations, and broader immunoreactivity to diverse targets due to larger rabbit immune repertoire
• This antibody has specificity for H1N1 (A/California/04/2009) HA H1N1 (A/California/07/2009) HA
• Infectious diseases are the leading cause of death worldwide
• AIDS, tuberculosis (TB), malaria, diarrhoeal and respiratory infections account for 78% of deaths caused by infectious disease
• As many infectious diseases are controlled, new diseases emerge and old diseases become resistant to current drugs
• Many infectious diseases have been associated with an increase risk of carcinoma
• Influenza continues to attract researchers as new strains appear by the ability of the influenza gene to mix with different forms of the virus
• Recently, research on SARS and West Nile virus has risen due to the increased number of infections
• These antibodies assist in research by detecting the infectious disease agent.